Inflammatory marker alteration in response to systemic therapies in psoriasis

Grechin,Cristina; Solovăstru,Laura   Gheucă; Vâță,Dan; Pătrașcu,Adriana  Ionela; Grăjdeanu,Alina  Ioana; Porumb‑Andrese,Elena

doi:10.3892/etm.2020.8535

Inflammatory marker alteration in response to systemic therapies in psoriasis

Authors:
- Cristina Grechin
- Laura Gheucă Solovăstru
- Dan Vâță
- Adriana Ionela Pătrașcu
- Alina Ioana Grăjdeanu
- Elena Porumb‑Andrese
View Affiliations

Affiliations: Department of Gastroenterology, Sligo University Hospital, Sligo, F91 H684, Ireland, Department of Dermatology, ‘Gr. T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania, Department of Dermatology, ‘Sf. Spiridon’ Clinical Emergency County Hospital, 700111 Iasi, Romania
Published online on: February 18, 2020 https://doi.org/10.3892/etm.2020.8535
Pages: 42-46
Copyright: © Grechin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Substantial research has focused on the presence of biomarkers involved in both the pathogenesis of psoriasis and its comorbidities. The identification of these biomarkers has a crucial role in establishing the diagnosis and prognosis, in understanding the physiopathological mechanism and in determining the therapeutic response. The aim of this study was to emphasize the alteration in inflammatory markers in response to systemic therapies in psoriasis. Evolution of inflammatory marker alteration was studied in 194 patients with psoriasis, aged between 7 and 87 years. Two groups were set up: the first comprised of patients treated with methotrexate (n=51), while the second comprised patients treated with biological therapy (n=143). Each group was evaluated for blood values of C‑reactive protein (CRP), erythrocyte sedimentation rate (ESR) and fibrinogen before and after treatment, the fluctuation of these values according to the treatment, the interrelation between inflammatory markers and inflammatory activity of the disease and the evolution of the disease after treatment. In group I, 46 out of 51 patients had elevated levels of acute phase reactants before treatment. After treatment with methotrexate 7.5 mg/week, 12 out of 46 patients had elevated blood levels of ESR and 18 out of 46 patients of CRP and fibrinogen. Before treatment with biological therapy, 138 patients out of 143 presented abnormal high range for acute phase reactants. After treatment with biological therapy, 18 patients out of 138 had elevated blood levels of ESR and 37 patients out of 138 had elevated CRP and fibrinogen. A favorable evolution was noted in 98 patients out of 138. It was concluded that the systemic treatment with both methotrexate and biological therapy showed a marked decline in the patients with abnormal values of CRP, ESR and fibrinogen, indirectly showing a decline in the inflammatory activity of psoriasis.

View Figures

View References

1	Lin X and Huang T: Co-signaling molecules in psoriasis pathogenesis: Implications for targeted therapy. Hum Immunol. 76:95–101. 2015.PubMed/NCBI View Article : Google Scholar
2	Ghosh A and Panda S: Recent understanding of the etiopathogenesis of psoriasis. Indian J Paediatr Dermatol. 18:1–8. 2017.
3	Caruntu C, Boda D, Dumitrascu G, Constantin C and Neagu M: Proteomics focusing on immune markers in psoriatic arthritis. Biomarkers Med. 9:513–528. 2015.PubMed/NCBI View Article : Google Scholar
4	Căruntu C, Boda D, Musat S, Căruntu A and Mandache E: Stress-induced mast cell activation in glabrous and hairy skin. Mediators Inflamm. 2014(105950)2014.PubMed/NCBI View Article : Google Scholar
5	Farshchian M, Ansar A, Sobhan M and Hoseinpoor V: C-reactive protein serum level in patients with psoriasis before and after treatment with narrow-band ultraviolet B. An Bras Dermatol. 91:580–583. 2016.PubMed/NCBI View Article : Google Scholar
6	Lowes MA, Suárez-Fariñas M and Krueger JG: Immunology of psoriasis. Annu Rev Immunol. 32:227–255. 2014.PubMed/NCBI View Article : Google Scholar
7	Li R, Wang J, Wang X, Zhou J, Wang M, Ma H and Xiao S: Increased βTrCP are associated with imiquimod-induced psoriasis-like skin inflammation in mice via NF-κB signaling pathway. Gene. 592:164–171. 2016.PubMed/NCBI View Article : Google Scholar
8	Pepys MB and Hirschfield GM: C-reactive protein: A critical update. J Clin Invest. 111:1805–1812. 2003.PubMed/NCBI View Article : Google Scholar
9	Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A and Teixeira F: The inflammatory response in mild and in severe psoriasis. Br J Dermatol. 150:917–928. 2004.PubMed/NCBI View Article : Google Scholar
10	Gisondi P, Lora V, Bonauguri C, Russo A, Lippi G and Girolomoni G: Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol. 168:749–755. 2013.PubMed/NCBI View Article : Google Scholar
11	Qu D, Liu J, Lau CW and Huang Y: IL-6 in diabetes and cardiovascular complications. Br J Pharmacol. 171:3595–3603. 2014.PubMed/NCBI View Article : Google Scholar
12	Devaraj S, Valleggi S, Siegel D and Jialal I: Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep. 12:110–118. 2010.PubMed/NCBI View Article : Google Scholar
13	Biljan D, Situm M, Kostović K, Batinac T and Matisić D: Acute phase proteins in psoriasis. Coll Antropol. 33:83–86. 2009.PubMed/NCBI
14	Isha, Jain VK and Lal H: C-reactive protein and uric acid levels in patients with psoriasis. Indian J Clin Biochem. 26:309–311. 2011.PubMed/NCBI View Article : Google Scholar
15	Negrei C, Ginghină O, Căruntu C, Burcea Dragomiroiu GT, Jinescu G and Boda D: Investigation relevance of methotrexate polyglutamates in biological systems by high performance liquid chromatography. Rev Chim. 66:766–768. 2015.
16	Boda D, Negrei C, Nicolescu F and Balalau C: Assessment of some oxidative stress parameters in methotrexate treated psoriasis patients. Farmacia. 62:704–710. 2014.
17	Zamanian A, Houshang Ehsani A, Bahareh Darvari S, Mehran G and Azizpour A: Trend of C-reactive protein anderythrocyte sedimentation rates in psoriatic patients on treatment of standard protocol of infliximab. GMJ. 4:8–13. 2015.
18	Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC and Dann F: Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 159:322–330. 2008.PubMed/NCBI View Article : Google Scholar
19	Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S, Economopoulos T, Stavrianeas NG and Katsambas A: The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol. 36:845–850. 2011.PubMed/NCBI View Article : Google Scholar
20	Olteanu R, Constantin MM, Zota A, Dorobantu DM, Constantin T, Serban ED, Balanescu P, Mihele D and Gheuca-Solovastru L: Original clinical experience and approach to treatment study with interleukine 12/23 inhibitor in moderate-to-severe psoriasis patients. Farmacia. 64:918–921. 2016.
21	Olteanu R, Zota A and Constantin M: Biosimilars: An update on clinical trials (review of published and ongoing studies). Acta Dermatovenerol Croat. 25:57–66. 2017.PubMed/NCBI
22	Coimbra S and Santos-Silva A: Biomarkers of psoriasis severity and therapy monitoring. World J Dermatol. 3:15–27. 2014.PubMed/NCBI View Article : Google Scholar
23	Gocalp H: Effect of psoriasis severity on inflammation parameters: Controlled study. Turk Arch Dermatol Venereol. 52:91–94. 2018.
24	Căruntu C, Boda D, Căruntu A, Rotaru M, Baderca F and Zurac S: In vivo imaging techniques for psoriatic lesions. Rom J Morphol Embryol. 55 (Suppl 3):1191–1196. 2014.PubMed/NCBI
25	Ilie MA, Caruntu C, Lixandru D, Tampa M, Georgescu SR, Constantin MM, Constantin C, Neagu M, Zurac SA and Boda D: In vivo confocal laser scanning microscopy imaging of skin inflammation: Clinical applications and research directions. Exp Ther Med. 17:1004–1011. 2019.PubMed/NCBI View Article : Google Scholar
26	Negrei C, Caruntu C, Ginghina O, Dragomiroiu GT, Toderescu CD and Boda D: Qualitative and quantitative determination of methotrexate polyglutamates in erythrocytes by high performance liquid chromatography. Rev Chim. 66:607–610. 2015.
27	Negrei C, Arsene AL, Toderescu CD, Boda D and Ilie M: Acitretin treatment in psoriasis may influence the cell membrane fluidity. Farmacia. 60:767–771. 2012.